| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.ATV.13.7.1090 |
| P953 | full work available at URL | https://www.ahajournals.org/doi/pdf/10.1161/01.ATV.13.7.1090 |
| P698 | PubMed publication ID | 7686395 |
| P2093 | author name string | F. Bachmann | |
| E. K. Kruithof | |||
| F. Lupu | |||
| G. E. Bergonzelli | |||
| D. A. Heim | |||
| E. Cousin | |||
| C. Y. Genton | |||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | plasminogen | Q107129060 |
| P304 | page(s) | 1090-1100 | |
| P577 | publication date | 1993-07-01 | |
| P1433 | published in | Arteriosclerosis and thrombosis : a journal of vascular biology | Q27709770 |
| P1476 | title | Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries | |
| P478 | volume | 13 |
| Q77799937 | 11-Keto-9(E),12(E)-octadecadienoic acid, a novel fatty acid that enhances fibrinolytic activity of endothelial cells |
| Q73137295 | A new butadiene derivative, T-686, inhibits plasminogen activator inhibitor type-1 production in vitro by cultured human vascular endothelial cells and development of atherosclerotic lesions in vivo in rabbits |
| Q73241789 | Accelerated plasminogen activator inhibitor may prevent late restenosis after coronary stenting in acute myocardial infarction |
| Q34545496 | Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction |
| Q41089038 | An endothelial storage granule for tissue-type plasminogen activator |
| Q39333523 | Causal Effect of Plasminogen Activator Inhibitor Type 1 on Coronary Heart Disease |
| Q35764595 | Chemical Antagonists of Plasminogen Activator Inhibitor-1: Mechanisms of Action and Therapeutic Potential in Vascular Disease |
| Q47687448 | Co-localization of fibrinolytic activators and inhibitors with macrophages in atherosclerotic vessels |
| Q31929744 | Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. |
| Q37350905 | Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide |
| Q73383686 | Donor PAI-1 expression inhibits the intimal response of early allograft vascular disease |
| Q92056401 | Effects of 17β-Estradiol on the Plasminogen Activator System in Vascular Smooth Muscle Cells Treated with Lysophophatidylcholine |
| Q52973694 | Effects of abciximab and tirofiban on vitronectin receptors in human endothelial and smooth muscle cells. |
| Q52533093 | Effects of lipids and lipoproteins on thrombosis and rheology. |
| Q35757741 | Effects of plasminogen activator inhibitor-1-specific RNA aptamers on cell adhesion, motility, and tube formation |
| Q54420587 | Elevated levels of plasminogen-activator inhibitor type 1 in atherosclerotic aorta. |
| Q35751580 | Expression of fibrinolytic genes in atherosclerotic abdominal aortic aneurysm wall. A possible mechanism for aneurysm expansion |
| Q37627304 | Expression of uPA, tPA, and PAI-1 in Calcified Aortic Valves. |
| Q34019901 | Extracellular histones are major mediators of death in sepsis |
| Q40492595 | Fibrinogen in Human Atherosclerosis |
| Q40406437 | Fibrinolysis and atherosclerosis |
| Q73681245 | Gene Polymorphisms for PAI-1 Are Associated with the Angiographic Extent of Coronary Artery Disease |
| Q30415902 | Genome-wide association study for circulating levels of PAI-1 provides novel insights into its regulation |
| Q28344912 | HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins |
| Q42212789 | Impact of lysophosphatidylcholine on the plasminogen activator system in cultured vascular smooth muscle cells |
| Q51424973 | Increased plasminogen activator inhibitor-1 levels in patients with isolated coronary artery ectasia. |
| Q24300523 | Induction of Apoptosis in Vascular Cells by Plasminogen Activator Inhibitor-1 and High Molecular Weight Kininogen Correlates with Their Anti-Adhesive Properties |
| Q54071069 | Lack of evidence for secretion of plasminogen activator inhibitor-1 by human subcutaneous adipose tissue in vivo. |
| Q42509254 | Ligustrazini inhibits endotoxin induced PAI-1 expression in human umbilical vein endothelial cells |
| Q73161353 | Normal and perturbed endothelial cells from canine femoral arteries and femoral veins exhibit heterogeneity in hemostatic properties and growth characteristics |
| Q46928150 | Notoginsenoside R1 from Panax notoginseng inhibits TNF-alpha-induced PAI-1 production in human aortic smooth muscle cells |
| Q35479955 | PAI-1 4G/5G polymorphism and coronary artery disease risk: a meta-analysis |
| Q71718204 | Pathophysiology of fibrinolysis |
| Q35765078 | Patterns of expression of fibrinolytic genes and matrix metalloproteinase-9 in dissecting aortic aneurysms |
| Q40406453 | Physiological consequences of over- or under-expression of fibrinolytic system components in transgenic mice |
| Q33664574 | Plasmin activation system in restenosis: role in pathogenesis and clinical prediction? |
| Q34384932 | Plasminogen activator inhibitor type-1 (part two): role for failure of thrombolytic therapy. PAI-1 resistance as a potential benefit for new fibrinolytic agents |
| Q34217461 | Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions |
| Q40305997 | Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis |
| Q33812093 | Plasminogen activator inhibitor-1 is an aggregate response factor with pleiotropic effects on cell signaling in vascular disease and the tumor microenvironment |
| Q34986710 | Plasminogen activator inhibitor-1: physiologic role, regulation, and the influence of common pharmacologic agents |
| Q42437670 | Production of plasminogen activator inhibitor-1 by human saphenous vein endothelial cells seeded onto endarterectomy surfaces in vitro |
| Q46228916 | Prothrombotic activation of pulmonary arterial endothelial cells in a patient with tuberculosis |
| Q32065346 | Quantitative analysis of specific mRNA species in minute cell samples by RT-PCR and flow cytometry |
| Q36254926 | Receptor-independent role of urokinase-type plasminogen activator in pericellular plasmin and matrix metalloproteinase proteolysis during vascular wound healing in mice |
| Q61955174 | Regulation of plasminogen activator inhibitor type 1 in cultured smooth muscle cells by interleukin 1α and tumour necrosis factor-α |
| Q36825046 | Regulatory role of microRNA-30b and plasminogen activator inhibitor-1 in the pathogenesis of cognitive impairment |
| Q28345650 | Remodeling of the vessel wall after copper-induced injury is highly attenuated in mice with a total deficiency of plasminogen activator inhibitor-1 |
| Q51830365 | Smooth muscle cells improve endothelial cell retention on polytetrafluoroethylene grafts in vivo. |
| Q36768488 | Statins as first-line therapy for acute coronary syndrome? |
| Q37276466 | Statins in the first-line therapy of acute coronary syndrome - similar to aspirin? |
| Q74348172 | Telomere attrition of the human abdominal aorta: relationships with age and atherosclerosis |
| Q83200066 | The Renin-Angiotensin and fibrinolytic systems co-conspirators in the pathogenesis of ischemic cardiovascular disease |
| Q38638020 | The role of tumor necrosis factor-like weak inducer of apoptosis in atherosclerosis via its two different receptors |
| Q35744631 | The vulnerable atherosclerotic plaque: pathogenesis and therapeutic approach |
| Q40903271 | Tumor necrosis factor alpha up-regulates in an autocrine manner the synthesis of plasminogen activator inhibitor type-1 during induction of monocytic differentiation of human HL-60 leukemia cells |
Search more.